Research into trans medicine has been manipulated
Research into trans medicine faces scrutiny following concerns raised by British paediatrician Hilary Cass about evidence for youth gender medicine. WPATH defends guidelines based on systematic reviews amid U.S. debate and upcoming Supreme Court case.
Read original articleResearch into trans medicine has been under scrutiny after a review by British paediatrician Hilary Cass raised concerns about the evidence base for youth gender medicine. The World Professional Association for Transgender Health (WPATH) responded by defending its guidelines, emphasizing they are based on more systematic reviews. This debate comes amidst the heated discussion in the U.S. regarding youth gender medicine, with an upcoming Supreme Court case challenging a ban in Tennessee. The case is expected to involve arguments about evidence and expert authority. Systematic reviews play a crucial role in evaluating medical evidence thoroughly. The controversy sheds light on the complexities surrounding research in trans medicine and the importance of robust evidence in guiding medical practices for transgender individuals.
Related
Top FDA official overrules staff to approve gene therapy that failed trial
The FDA approved Elevidys gene therapy for Duchenne muscular dystrophy, despite controversy over failed trials. Dr. Peter Marks led the decision, facing criticism for prioritizing emotional arguments over scientific evidence.
Research into homeopathy: data falsification, fabrication and manipulation
Research on homeopathy faces credibility issues due to data manipulation in a study led by Michael Frass. The study, once positive, now raises concerns of scientific misconduct, urging withdrawal of publication. Challenges persist in alternative medicine research, highlighting the conflict between ideology and scientific integrity.
The Silence Doctors Are Keeping About Millennial Deaths
Physicians avoid discussing mortality with young cancer patients, impacting care quality. Challenges include fertility, finances, and missed opportunities. Open, compassionate conversations are crucial for patient-centered decision-making, emphasizing values and preferences.
China bans clinical research in germline genome editing as 'irresponsible'
China bans clinical research on germline genome editing due to ethical concerns, following He Jiankui's controversial gene-editing of babies. The new guideline stresses ethical considerations and prohibits heritable changes in DNA. Other countries have similar restrictions.
The booming business of shaming young men
Online health providers like Hims & Hers Health and Ro target young men's insecurities, offering products for issues like hair loss and erectile dysfunction. Critics warn about potential risks and ethical concerns.
Case in point, plucking out this single instance of weird behavior and slapping on this clickbait title that implies a much more widespread problem. Journalism has completely given over to feeding “well-actually” transphobia for clicks.
Like begets like, but in opposition. Radicals beget radicals, the right and the left. Male chauvinism ruled the world, but a feminist movement arises, among some, overshoots into female chauvinism, begetting renewed male chauvinistic radicalism.
Radicalism is often necessary to effect change, because radicals don't see nuance, and when you don't see nuance, taking action...even risky action, is easier to justify.
The story has been told millions of times.
If you want better science in gender affirming care: 1) fund it, 2) don't make it scary for the scientists who do study it, as death threats are the norm, 3) dont interpret studies with preexisting agendas.
Identifying who will and who will not benefit from gender affirming care is important, but investigating one or the other can't be seen as claiming allegiance to one camp or another.
I support LGBT rights, but that doesn't mean we should discount medical advice.
It's the typical problem of people who refuse to listen to doctors and want to self diagnose and self medicate.
Related
Top FDA official overrules staff to approve gene therapy that failed trial
The FDA approved Elevidys gene therapy for Duchenne muscular dystrophy, despite controversy over failed trials. Dr. Peter Marks led the decision, facing criticism for prioritizing emotional arguments over scientific evidence.
Research into homeopathy: data falsification, fabrication and manipulation
Research on homeopathy faces credibility issues due to data manipulation in a study led by Michael Frass. The study, once positive, now raises concerns of scientific misconduct, urging withdrawal of publication. Challenges persist in alternative medicine research, highlighting the conflict between ideology and scientific integrity.
The Silence Doctors Are Keeping About Millennial Deaths
Physicians avoid discussing mortality with young cancer patients, impacting care quality. Challenges include fertility, finances, and missed opportunities. Open, compassionate conversations are crucial for patient-centered decision-making, emphasizing values and preferences.
China bans clinical research in germline genome editing as 'irresponsible'
China bans clinical research on germline genome editing due to ethical concerns, following He Jiankui's controversial gene-editing of babies. The new guideline stresses ethical considerations and prohibits heritable changes in DNA. Other countries have similar restrictions.
The booming business of shaming young men
Online health providers like Hims & Hers Health and Ro target young men's insecurities, offering products for issues like hair loss and erectile dysfunction. Critics warn about potential risks and ethical concerns.